Skip to Content

Head and Neck Cancer Trials

HCN Tissue Bank: Tissue/Body Fluid Procurement and Clinical Data Collection for Patients with Malignancies of the Head and Neck Area and/or Pre-Malignant Changes
Aims: The purpose of this study is to collect tissue, blood, saliva, and/or clinical data (information about your treatment) from patients with a cancer in the head and neck area (or pre-malignant lesions) for research purposes. Certain genetic and biochemical changes are believed to lead to the development of head and neck cancer. Scientists are attempting to discover and understand the function of these changes. In the future, improved understanding of these changes may help us to better detect head and neck cancers and offer improved treatments.
Principal Investigator: Nicholas Campbell, MD
IRB Approval Number: EH13-276
Sponsor: NorthShore University HealthSystem
Contact: Interested patients should contact research nurse Elita Fine, RN at 847.570.2698
Open to Enrollment: Yes

RTOG-1216: Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered with Concurrent Cisplatin versus Docetaxel versus Docetaxel and Cetuximab for High-Risk Squamous Cell cancer of the Head and Neck
Aims: The purpose of this part of this study is to find out what effects, good and/or bad, one of the following treatments has on you and your cancer. In this part of the study, you will receive one of the following treatments:

  • Standard treatment: radiation therapy and cisplatin
  • Experimental treatment: radiation therapy and docetaxel
  • Experimental treatment: radiation therapy, docetaxel, and cetuximab

Principal Investigator: Bruce Brockstein, MD
IRB Approval Number: EH15-004
Sponsor: NRG Oncology
Contact: Interested patients should contact research nurse Elita Fine, RN at 847.570.2698
Open to Enrollment- suspended

 

EA3132: Phase II Randomized Trial of Radiotherapy with or without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) with TP53 Sequencing
Aims: The purpose is to compare 2 treatment approaches currently used after surgery for head and neck cancer. One treatment is radiation therapy and the other is radiation therapy with cisplatin.
Principal Investigator: Bruce Brockstein, MD
IRB Approval Number: 
EH18-068
Sponsor:  ECOG-ACRIN
Contact: Interested patients should contact research nurse Elita Fine, RN at 847.570.2698
Open to Enrollment:
yes

Enzychem EC-18-202: A Phase 2, Multi-center, Randomized, Double-blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of EC-18 in Altering the Severity and Course of Oral Mucositis in Patients Being Treated with Concomitant Chemoradiation Therapy for Cancers of the Mouth, Oropharynx, Phyopharynx, and Nasopharynx
Aims: 
The purpose of this study is to compare any good and bad effects of using EC-18 in reducing mouth sores in patients receiving chemotherapy and radiation at the same time.
Diagnosis: 
Head and Neck Cancer
Principal Investigator: Nicholas Campbell, MD
IRB Approval Number: EH18-318
Sponsor:
Enzychem
Contact:
Interested patients should contact research nurse Elita Fine, RN at 847.570.2698
Open to Enrollment:
 Yes     

 

Merck 3475-689: A Phase III Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination with Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)
Aims: 
The purpose of this study is to compare any good and bad effects of adding pembrolizumab to radiation and chemotherapy before and after surgery.
Diagnosis: 
Head and Neck Cancer
Principal Investigator: Nicholas Campbell, MD
IRB Approval Number: EH18-073
Sponsor: Merck
Contact:
Interested patients should contact research nurse Elita Fine, RN at 847.570.2698
Open to Enrollment:
 Yes